Depression in Schizophrenia Patients with Tardive Dyskinesia

지연성 이상운동이 있는 조현병 환자의 우울증

  • Cha, Seongjae (Department of Psychiatry, Gongju National Hospital) ;
  • Oh, Keun (Department of Psychiatry, Gongju National Hospital) ;
  • Kim, Misuk (Department of Psychiatry, Gongju National Hospital) ;
  • Park, Seon-Cheol (Department of Psychiatry, Inje University Haeundae Paik Hospital) ;
  • Kim, Young Hoon (Department of Psychiatry, Gongju National Hospital)
  • 차성재 (국립공주병원 정신건강의학과) ;
  • 오근 (국립공주병원 정신건강의학과) ;
  • 김미숙 (국립공주병원 정신건강의학과) ;
  • 박선철 (인제대학교 해운대백병원 정신건강의학과) ;
  • 김영훈 (국립공주병원 정신건강의학과)
  • Received : 2018.06.08
  • Accepted : 2018.10.10
  • Published : 2018.11.30

Abstract

Objectives This study aimed to investigate the relationship between depressive and anxiety symptoms and tardive dyskinesia (TD) and reveal the association of cognitive function and TD in patients with schizophrenia. Methods We recruited 30 schizophrenia patients with TD and 31 without TD from a national mental hospital in South Korea. To assess depressive and anxiety symptoms, the Beck Depression Inventory-II (BDI-II) and the Beck Anxiety Inventory (BAI) were conducted. Using the five-factor structure of the BDI-II and BAI, somatic anxiety, cognitive depression, somatic depression, subjective anxiety, and autonomic anxiety were assessed. Computerized neurocognitive function test (CNT) was performed to assess levels of cognitive functions. We compared the clinical characteristics, levels of cognitive functions, and depressive and anxiety symptoms between schizophrenia patients with TD and without TD. Chi-square test, Fisher's exact test, independent t-test and Mann Whitney U test were conducted to compare two groups. Pearson correlation analysis was conducted to evaluate relationships among the abnormal involuntary movement scale (AIMS), BDI-II, BAI, somatic anxiety, cognitive depression, somatic depression, subjective anxiety, and autonomic anxiety. Results The subjects with TD had significantly lower score on the cognitive depression than those without TD (t = -2.087, p = 0.041). There were significant correlations between the AIMS score and the BDI-II score (r = -0.386, p = 0.035) and between the AIMS score and cognitive depression score (r = - 0.385, p = 0.035). Conclusions Our findings suggest the inverse relationship between severities in TD and depression and support the assumption that there is an inverse relationship between the pathophysiology of TD and depression.

Keywords

References

  1. Jeste DV, Caligiuri MP. Tardive dyskinesia. Schizophr Bull 1993;19:303-315. https://doi.org/10.1093/schbul/19.2.303
  2. Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 2008;21:151-156. https://doi.org/10.1097/YCO.0b013e3282f53132
  3. Remington G. Tardive dyskinesia: eliminated, forgotten, or overshadowed? Curr Opin Psychiatry 2007;20:131-137. https://doi.org/10.1097/YCO.0b013e328017f6b1
  4. Lerner PP, Miodownik C, Lerner V. Tardive dyskinesia (syndrome): current concept and modern approaches to its management. Psychiatry Clin Neurosci 2015;69:321-334. https://doi.org/10.1111/pcn.12270
  5. O'Brien A. Comparing the risk of tardive dyskinesia in older adults with first-generation and second-generation antipsychotics: a systematic review and meta-analysis. Int J Geriatr Psychiatry 2016;31:683-693. https://doi.org/10.1002/gps.4399
  6. Browne S, Roe M, Lane A, Gervin M, Morris M, Kinsella A, et al. Quality of life in schizophrenia: relationship to sociodemographic factors, symptomatology and tardive dyskinesia. Acta Psychiatr Scand 1996;94:118-124. https://doi.org/10.1111/j.1600-0447.1996.tb09835.x
  7. Ballesteros J, Gonzalez-Pinto A, Bulbena A. Tardive dyskinesia associated with higher mortality in psychiatric patients: results of a meta-analysis of seven independent studies. J Clin Psychopharmacol 2000;20:188-194. https://doi.org/10.1097/00004714-200004000-00011
  8. Youssef HA, Waddington JL. Morbidity and mortality in tardive dyskinesia: associations in chronic schizophrenia. Acta Psychiatr Scand 1987;75:74-77. https://doi.org/10.1111/j.1600-0447.1987.tb02754.x
  9. Emsley RA, Oosthuizen PP, Joubert AF, Roberts MC, Stein DJ. Depressive and anxiety symptoms in patients with schizophrenia and schizophreniform disorder. J Clin Psychiatry 1999;60:747-751. https://doi.org/10.4088/JCP.v60n1105
  10. Cutler NR, Post RM, Rey AC, Bunney WE Jr. Depression-dependent dyskinesias in two cases of manic-depressive illness. N Engl J Med 1981;304:1088-1089. https://doi.org/10.1056/NEJM198104303041807
  11. de Potter RW, Linkowski P, Mendlewicz J. State-dependent tardive dyskinesia in manic-depressive illness. J Neurol Neurosurg Psychiatry 1983;46:666-668. https://doi.org/10.1136/jnnp.46.7.666
  12. Kane JM. Tardive dyskinesia in affective disorders. J Clin Psychiatry 1999;60 Suppl 5:43-47; discussion 48-49.
  13. Rush M, Diamond F, Alpert M. Depression as a risk factor in tardive dyskinesia. Biol Psychiatry 1982;17:387-392.
  14. Keshavan MS, Goswamy U. Tardive dyskinesia less severe in depression. Br J Psychiatry 1983;142:207-208. https://doi.org/10.1192/bjp.142.2.207
  15. Perenyi A, Norman T, Burrows GD. Relationship of symptomatology of schizophrenia and tardive dyskinesia. Eur Neuropsychopharmacol 1992;2:51-55. https://doi.org/10.1016/0924-977X(92)90036-8
  16. Alptekin K, Akvardar Y, Kivircik Akdede BB, Dumlu K, Isik D, Pirincci F, et al. Is quality of life associated with cognitive impairment in schizophrenia? Prog Neuropsychopharmacol Biol Psychiatry 2005;29:239-244. https://doi.org/10.1016/j.pnpbp.2004.11.006
  17. Braff DL, Geyer MA. Sensorimotor gating and schizophrenia. Human and animal model studies. Arch Gen Psychiatry 1990;47:181-188. https://doi.org/10.1001/archpsyc.1990.01810140081011
  18. Goldberg TE, Weinberger DR. Probing prefrontal function in schizophrenia with neuropsychological paradigms. Schizophr Bull 1988; 14:179-183. https://doi.org/10.1093/schbul/14.2.179
  19. Saykin AJ, Gur RC, Gur RE, Mozley PD, Mozley LH, Resnick SM, et al. Neuropsychological function in schizophrenia. Selective impairment in memory and learning. Arch Gen Psychiatry 1991;48:618-624. https://doi.org/10.1001/archpsyc.1991.01810310036007
  20. Waddington JL, Youssef HA. Late onset involuntary movements in chronic schizophrenia: relationship of 'tardive' dyskinesia to intellectual impairment and negative symptoms. Br J Psychiatry 1986;149: 616-620. https://doi.org/10.1192/bjp.149.5.616
  21. Davis EJ, Borde M, Sharma LN. Tardive dyskinesia and type II schizophrenia. Br J Psychiatry 1992;160:253-256. https://doi.org/10.1192/bjp.160.2.253
  22. Kolakowska T, Williams AO, Ardern M, Reveley MA. Tardive dyskinesia in schizophrenics under 60 years of age. Biol Psychiatry 1986; 21:161-169. https://doi.org/10.1016/0006-3223(86)90143-5
  23. Myslobodsky MS. Anosognosia in tardive dyskinesia: "tardive dysmentia" or "tardive dementia"? Schizophr Bull 1986;12:1-6. https://doi.org/10.1093/schbul/12.1.1
  24. Wegner JT, Kane JM, Weinhold P, Woerner M, Kinon B, Lieberman J. Cognitive impairment in tardive dyskinesia. Psychiatry Res 1985; 16:331-337. https://doi.org/10.1016/0165-1781(85)90124-6
  25. Yu BH, Kim JH, Bae JM, Lee KU, Woo JM, Kim SP. Cognitive dysfunctions in positive and negative schizophrenic patients with or without tardive dyskinesia. J Korean Neuropsychiatr Assoc 1998;37:38-47.
  26. Pantelis C, Stuart GW, Nelson HE, Robbins TW, Barnes TR. Spatial working memory deficits in schizophrenia: relationship with tardive dyskinesia and negative symptoms. Am J Psychiatry 2001;158:1276-1285. https://doi.org/10.1176/appi.ajp.158.8.1276
  27. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: American Psychiatric Association Publishing;2013. p.99-105.
  28. Guy W. ECDEU Assessment Manual for Psychopharmacology. Washington, DC: US Department of Health, and Welfare;1976. p.534-537.
  29. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982;39:486-487.
  30. Wu JQ, Chen DC, Tan YL, Tan SP, Hui L, Lv MH, et al. Altered BDNF is correlated to cognition impairment in schizophrenia patients with tardive dyskinesia. Psychopharmacology (Berl) 2015;232:223-232. https://doi.org/10.1007/s00213-014-3660-9
  31. Lane RD, Glazer WM, Hansen TE, Berman WH, Kramer SI. Assessment of tardive dyskinesia using the Abnormal Involuntary Movement Scale. J Nerv Ment Dis 1985;173:353-357. https://doi.org/10.1097/00005053-198506000-00005
  32. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276. https://doi.org/10.1093/schbul/13.2.261
  33. Yi JS, Ahn YM, Shin HK, An SK, Joo YH, Kim SH, et al. Reliability and Validity of the Korean Version of the Positive and Negative Syndrome Scale. J Korean Neuropsychiatr Assoc 2001;40:1090-1105.
  34. Kay SR, Opler LA, Lindenmayer J-P. The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br J Psychiatry Suppl 1989;7:59-67.
  35. Kane RL, Kay GG. Computerized assessment in neuropsychology: a review of tests and test batteries. Neuropsychol Rev 1992;3:1-117. https://doi.org/10.1007/BF01108787
  36. Ha KS, Kwon JS, Lyoo IK, Kong SW, Lee DW, Youn T. Development and standardization process, and factor analysis of the computerized cognitive function test system for Korea adults. J Korean Neuropsychiatr Assoc 2002;41:551-562.
  37. Ha KS, Kwon JS, Lyoo IK. Development and standardization of the computerized attention assessment for Korean adults. J Korean Neuropsychiatr Assoc 2002;41:335-346.
  38. Kwon JS, Lyoo IK, Hong KS, Yeon BK, Ha KS. Development and standardization of the computerized memory assessment for Korean adults. J Korean Neuropsychiatr Assoc 2002;41:347-362.
  39. Lyoo IK, Kwon JS, Ha KS. Development and standardization of the computerized higher cortical function assessment for Korean adults. J Korean Neuropsychiatr Assoc 2002;41:538-550.
  40. Lee HK, Lee EH, Hwang ST, Hong SH, Kim JH. Psychometric properties of the Beck Anxiety Inventory in the community-dwelling sample of Korean adults. Kor J Clin Psychol 2016;35:822-830. https://doi.org/10.15842/kjcp.2016.35.4.010
  41. Sung HM, Kim JB, Park YN, Bai DS, Lee SH, Ahn HN. A study on the reliability and the validity of Korean version of the Beck Depression Inventory-II (BDI-II). J Korean Soc Biol Ther Psychiatry 2008;14:201-212.
  42. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988;56:893-897. https://doi.org/10.1037/0022-006X.56.6.893
  43. Clark LA, Watson D. Theoretical and empirical issues in differentiating depression from anxiety. In: Becker J, Kleinman A, editors. Psychosocial Aspects of Depression. Hillsdale, NJ: Lawrence Erlbaum Associates, Inc.;1991. p.39-65.
  44. Feldman LA. Distinguishing depression and anxiety in self-report: evidence from confirmatory factor analysis on nonclinical and clinical samples. J Consult Clin Psychol 1993;61:631-638. https://doi.org/10.1037/0022-006X.61.4.631
  45. Hewitt PL, Norton GR. The Beck Anxiety Inventory: a psychometric analysis. Psychol Assess 1993;5:408-412. https://doi.org/10.1037/1040-3590.5.4.408
  46. Lee K, Kim D, Cho Y. Exploratory factor analysis of the Beck Anxiety Inventory and the Beck Depression Inventory-II in a psychiatric outpatient population. J Korean Med Sci 2018;33:e128. https://doi.org/10.3346/jkms.2018.33.e128
  47. Gardner DM, Murphy AL, O'Donnell H, Centorrino F, Baldessarini RJ. International consensus study of antipsychotic dosing. Am J Psychiatry 2010;167:686-693. https://doi.org/10.1176/appi.ajp.2009.09060802
  48. Schildkraut JJ. Depressions and biogenic amines. In: Arieti S, editor. American Handbook of Psychiatry. Vol 6. New York, NY: Basic Books;1975. p.9-32.
  49. Sitaram N, Gillin JC. Development and use of pharmacological probes of the CNS in man: evidence of cholinergic abnormality in primary affective illness. Biol Psychiatry 1980;15:925-955.
  50. Burt DR, Creese I, Snyder SH. Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. Science 1977;196:326-328. https://doi.org/10.1126/science.847477
  51. Seeman P. Targeting the dopamine D2 receptor in schizophrenia. Expert Opin Ther Targets 2006;10:515-531. https://doi.org/10.1517/14728222.10.4.515
  52. Ito H, Takano H, Takahashi H, Arakawa R, Miyoshi M, Kodaka F, et al. Effects of the antipsychotic risperidone on dopamine synthesis in human brain measured by positron emission tomography with l-[$\beta$-11C]DOPA: a stabilizing effect for dopaminergic neurotransmission? J Neurosci 2009;29:13730-13734. https://doi.org/10.1523/JNEUROSCI.4172-09.2009
  53. Ashby FG, Isen AM, Turken AU. A neuropsychological theory of positive affect and its influence on cognition. Psychol Rev 1999;106:529-550. https://doi.org/10.1037/0033-295X.106.3.529